In recognition of Dr. Farrell’s long and valuable service as chair, the board of directors appointed him to the new director position of chair emeritus, effective immediately.
Key facts
Extracted from this filing and checked against the source text.
Earnings ReleasesSEC 8-K Item 2.02confidence 0.9
RESMED INC reported the quarter ended December 31, 2022 results: revenue $ 1,033.7, net income $ 224.9, EPS $ 1.53.
Period
the quarter ended December 31, 2022
Revenue
$ 1,033.7
Net income
$ 224.9
EPS
$ 1.53
Result
reported results
Exact text from the filing
Three Months Ended December 31, 2022 December 31, 2021 % Change Constant Currency (A) Revenue $ 1,033.7 $ 894.9 16 % 20 % Gross margin 56.1 % 56.4 % (1 ) Non-GAAP gross margin (B) 56.8 % 57.6 % (1 ) Selling, general, and administrative expenses 211.7 185.4 14 20 Research and development expenses 69.9 62.5 12 15 Income from operations 280.2 248.7 13 Non-GAAP income from operations (B) 305.5 267.7 14 Net income 224.9 201.8 11 Non-GAAP net income (B) 244.4 216.2 13 Diluted earnings per share $ 1.53 $ 1.37 12 Non-GAAP diluted earnings per share (B) $ 1.66 $ 1.47 13
Dr. Peter C. Farrell was appointed as chair emeritus at RESMED INC.
Action
appointed
Role
chair emeritus
Exact text from the filing
In recognition of Dr. Farrell’s long and valuable service as chair, the board of directors appointed him to the new director position of chair emeritus, effective immediately.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.